Although peritoneal dialysis (PO) had been used since the early 60's, it was the introduction of continuous ambulatory peritoneal dialysis (CAPO) in the late 70's that established chronic peritoneal dialysis (CPO) as the equivalent of chronic hemodialysis (HO). According to industrial estimates, by the end of 1995 more than 100,000 patients with end-stage renal disease were undergoing some form of CPO worldwide (1) . While many patients have survived on HO for longer than ten years, only relatively few patients have managed to stay on PO for more than eight or ten years. The patients surviving longest on CPO tend to be young, female, and non-diabetics. They have few comorbid diseases, low body weight, and only a few episodes of peritonitis (2) .
Limiting the successful application of PO for long periods is the high rate of technique failure and mortality, which although comparable to that of HO remains excessive. Experience accumulated so far allows us to recognize most of the causes of both technique failure and death in CPO patients.
This editorial will discuss these causes and will examine some areas of improvement that might make CPO an effective and satisfactory mode of dialysis for longer periods.
Technique failure
One of the most common causes of technique failure and subsequent transfer of patients from PO to HO is peritonitis and/or exit-site infection (3) (4) (5) .
In most European and North American centers the introduction of the double-bag disconnect systems, with or without the use of a disinfectant, has reduced the peritonitis rate to an average of one episode per 24 patients months (6) . However, many CAPO patients still have repeated episodes of peritonitis or severe episodes, usually due to Staph. aureus or Pseudomonas. Such episodes may greatly damage the peritoneal membrane and reduce its ultrafiltration capacity, which by itself may result in dropout from CPO. It may also require catheter removal, interruption of PO and "temporary" transfer to HO, which in more than 50% of the cases becomes permanent.
Prevention of peritonitis
Oespite continuous and intensive efforts to create a "perfect" exit-site providing a complete bacterial barrier, peritonitis associated with exit site and/or tunnel infection remains a common cause of technique failure in CPO patients. Preventing peritonitis requires the development of appropriate procedural protocols and the careful training of patients (7) , the application of strict sterile conditions during connections and disconnections, and the use of disinfectants on all areas exposed to possible contamination.
The double-bag disconnect system and various other types of sterile connections have reduced mainly the peritonitis caused by intraluminal contamination (mainly Staph. epidermidis). They have not affected appreciably the peritonitis caused by other routes of contamination, nor that caused by Staph. aureus (8) .
The current diagnostic criteria for peritonitis rely upon cloudiness of the fluid, signs of peritoneal irritation or inflammation, and the presence of bacteria in the dialysate. All these develop usually within six to 24 hours after contamination. Earlier diagnosis and possibly more effective treatment would be helped by a faster, more sensitive, and specific diagnostic tool for peritonitis.
In severe peritonitis or that which persists despite appropriate antibiotic treatment, one should not hesitate to remove the catheter in order to prevent peritoneal membrane failure and death (9) . In such cases, we should establish safe ways (catheters coated with antibiotics?) to replace catheters at one sitting and thus avoid interruption of CPO, because many of these patients who have to be submitted to temporary HO do not return to CPO. Although not clinically proven, it seems prudent to use prophylactic antibiotics during catheter insertion, dental manipulations, and endoscopic procedures such as cystoscopy and colonoscopy (Vas S -personal communication).
In recent years, peritoneal catheters have been greatly improved, but we need to continue our efforts to develop newer catheter and cuff materials that will provide effective bacterial barriers and so prevent periluminal contamination. The role of mupirocin, either intranasally (10) or at the exit site (11) , should be established and its use should be simplified. Catheters of larger diameter also would decrease the exchange time. New catheter designs and completely fail-safe connection devices will reduce exit-site and tunnel infection and thus lower the rates of peritonitis.
Although it is difficult to predict who will incur frequent peritonitis episodes, obviously compliant patients, who have the intellectual capabilities to absorb training and who have good family support do better on CPO and have lower peritonitis rates. Patients with extensive skin disease (eczema, pemphigus), colostomies and extensive intraabdominal adhesions, or who are blind and have no helper, should be considered for CAPO only with great caution.
Patients' choice
Another increasingly important factor in technique failure on CAPO is the "burnout" of patients and their partners or helpers. Increasingly partners are no longer willing to assist their CAPO relatives or simply are not available (3). Also some patients will refuse to increase the number of bag exchanges or the dialysate volume to compensate for the loss of the residual renal function, while others will resist any change in their previous routine that may be needed for a modification in their treatment.
Some of these patients could be switched to a nocturnal automated PO (APO) or to a combination of day and night time PD. At this point, the availability of small convenient, safe, simple-to-use, cost-saving cyclers that make solutions from concentrate will do much to prevent technique failure in PD. Also much simplified sophisticated cyclers would allow the delivery of adequate dialysis to patients underdialyzed on CAPO. For those patients wanting to interrupt CAPO because of fatigue, erythropoietin may be useful because it reduces generalized weakness and fatiguability.
Adequacy of dialysis
The National Cooperative Dialysis Study (12) on HO patients gave rise to the concept that small-solute clearance influences patient morbidity and thus was extrapolated to PO population (13) . Evidence from the CANUSA study has supported the decision to define adequate dialysis in CAPO patients in terms of small solute clearance (14) . This multi-center, prospective, cohort study of 698 new CAPO patients followed for two years showed longer survival in those patients who had an increased total (peritoneal plus residual) KTN at the beginning of treatment.
However, the minimum amount of dialysis that could be called "adequate" has not been determined. It now appears that a total weekly creatinine clearance of >60U1.73 m 2 and a KTN of > 2.0 could be considered as target CAPO dose. In the future we should agree to base adequacy of dialysis not only on urea kinetics but also on other parameters such as clearance of middle molecules, nutritional indices, and quality of life.
The CANUSA and other studies have emphasized the 130 significance of residual renal function because its loss over time accounts for the reduction in total clearance. It is not known, however, if augmenting dialysis clearance by larger volumes (2.5-3.0L), by more bag exchanges, or by switching to APO can compensate for the loss of renal function and improve survival. Adjustments in peritoneal dialysis dose should be made with the method that causes the least interference with the patient's lifestyle (tailored PO).
Clearly the preservation of residual kidney function is of the utmost importance. This calls for the avoidance of factors causing deterioration in residual renal function such as hypotension, hypertension, hypokalemia, acidosis, nephrotoxic medications -contrast media, aminoglycosides and other antibiotics and non-steroidal anti-inflammatory medications.
PO solutions -osmotic agents
We may also expect improvements in peritoneal dialysis solutions and osmotic agents, because the current use of glucose in almost all commercially available peritoneal dialysis solutions falls short of the ideal. The adverse metabolic effects of glucose-based PO solutions are well recognized. Recent biocompatibility studies have further raised the possibility of long-term toxic effects on peritoneal resident cells (15, 16) . The viability of peritoneal mesothelial cells is endangered by the hypertonicity (385-510 mOSm/kg), low pH (5.0-5.5), the presence of toxic glucose degradation products, and their reaction to local cytokine and toxic free-radical production. Mesothelial damage may lead to peritoneal fibrosis (rarely sclerosis) and loss of ultrafiltration and regeneration capacity. Years of exposure to such solutions may also increase the susceptibility of the peritoneal membrane to infection.
In vivo and in vitro studies have shown that lactate solutions, in combination with a low pH, impair the function of peritoneal cells. Lactate solutions are also less biocompatible than bicarbonate-containing solutions in terms of mesothelial cell growth, phospholipid secretion, and cytotoxic damage (17) . The ideal dialysis solution should mimic the extracellular fluid as closely as possible. It should have a neutral pH, be normotonic but able to induce transperitoneal ultrafiltration, and contain as a buffer mainly bicarbonate (but perhaps also lactate, pyruvate, beta-hydroxybutyrate and acetate in minor quantities). Also it should induce minimal intraperitoneal inflammatory reaction and enhance peritoneal resistance to injury (18) . So far glucose polymers seem to be promising osmotic agents. The containers used should be biocompatible and not add unwanted substances to the dialysate. Last but not least, these "ideal" products should be affordable.
Nutritional status
Malnutrition, common among CAPO patients (25-40%) (19) , lowers both technique and patient survival. Chronic calorie and protein undernutrition increases susceptibility to infection, impairs wound healing, increases anemia, decreases strength, and contributes to cardiovascular dysfunction, sexual impairment, progressive neuropathy, fatigue, generalized weakness, failure of rehabilitation, poor quality of life, and high risk of dying. The nutritional status of PO patients should be evaluated regularly. The physicians should be alert to diagnose and treat malnutrition effectively and promptly. The role of intraperitoneal amino acids, anabolic steroids and growth hormones in preventing or treating malnutrition although promising, requires further study.
Mortality
Studies comparing long-term survival on PO and HO have used to Cox Proportional Hazards Model and have yielded different results. Findings from the Canadian Registry suggest that the relative risk of death with HO is not higher than with CAPO (20) . A recent study from the USA found a higher risk of death on CAPO than on HO (21) . Other studies showed no difference in the relative risk of death related to mode of dialysis (3) . The comparison becomes more complex by the findings of the CANUSA study, where for comparable populations achieving the same weekly clearances the risk of death on PO in the USA is higher than the same risk in Canada (14) . These differences may reflect variations in case mix, the inability of the Cox model to correct for all possible differences, and a center or country effect. Thus so far one cannot estimate the true impact of choice of dialysis modality on survival. This issue will remain controversial until we have done a prospective randomized trial.
Although the mortality of patients undergoing HO and PO is steadily decreasing, patient survival on both techniques is far below that of the age-and gender-matched general population. Of all factors cardiovascular disease remains the most common cause of mortality, accounting for more than 50% of deaths in most studies (22) .
According to the 1995 USROS data base for the year 1991-1992 (21), the overall cardiovascular/cerebrovascu-lar death rates were marginally higher in diabetic CAPO/APO patients than in diabetic HO patients, whereas overall death rates from cardiovascular/cerebrovascular disease were lower in non-diabetic CAPO/APO patients than in non-diabetic HO patients.
To date the impact of treatment of cardiovascular disease on survival in dialysis patients remains incompletely delineated. In some studies 2.5-5.0% (22) perioperative mortality rates for coronary artery bypass grafting were acceptable but in others they were very high -up to 20% (23) . Coronary artery by-pass grafting increases survival in dialysis patients. Percutaneous transluminal coronary angioplasty (PTCA) is often successful, but early restenosis occurs with disproportionately high frequency (22) . Thus, we remain uncertain about the long-term impact of PTCA on survival of these patients. Likewise little is known about the effects of medical therapy of coronary artery disease and congestive heart failure on survival (22) . Correcting anemia with erythropoietin may improve survival of patients with anemia-related cardiomyopathy (23) .
We need to know more about the impact of lipid abnormalities on the mortality of persons on dialysis. This relationship should be delineated and we should establish therapeutic and preventive guidelines without delay. Much remains to be learned about the influence of cardiovascular disease on survival of dialysis patients. In the meantime we must continue our efforts towards effective control or elimination of other cardiovascular risk factors such as hypertension, hyperlipoproteinemia, and cigarette smoking. Also we should explore the routine use of acetylsalicylic acid and angiotension-converting enzyme inhibitors in diabetics on CAPO.
In PO patients the second leading cause of death is infection, usually as severe peritonitis with or without concomitant exit-site infection (3, 21) . As discussed above, prevention of peritonitis, immediate and effective treatment and, when indicated, early removal of the peritoneal catheter and temporary use of HO will decrease the risk of death. Cachexia or severe malnutrition, another frequent cause of death in PO population, also should be prevented and treated (3) . As shown in the CANUSA and other studies, mortality of CPO patients is closely related to dialysis adequacy. Hence the provision of adequate dialysis will reduce both technique failure and patient mortality.
We can expect that investigations now in progress will establish the importance of advanced glycosylated end products (AGE's) such as peritoneal glycosylated proteins and lipids that affect various components of the peritoneal membrane and blood vessels. Anti-glycosylation medications such as aminoguanidine (pimagedine) promise to control or even reverse the advanced glucosylation effects (24) . Hopefully, this measure will maintain the integrity and function of the peritoneal membrane for longer periods, preserve residual kidney function, delay the onset of micro and macro-angiopathy and amyloidosis, and thus reduce the morbidity and mortality of CPO patients.
Through discoveries in molecular biology and recombinant technology, we may be able to stimulate mesothelial cells to produce erythropoietin and vitamin 0, to metabolize beta-2 microglobulin, or even to synthesize various polypeptides from urea, as micro-organisms in the gastrointestinal tract of cattle are able to do. ment of exit-site infection and peritonitis, to optimize the dialysate volume and the use of automated PD. In these endeavours the International Society for Peritoneal Dialysis could play an important role, by coordinating international studies that address important issues, by promoting education, and by providing and regularly revising guidelines for "evidence-based" practice of CAPD/APD.
